Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

Improved dosing formula for warfarin (Coumadin)

Doctors prescribing blood thinners have had to go through a lengthy trial-and-error process to arrive at the optimal dose for their patients.

5 Sep 2007

Genetic-based dosing in orthopedic patients beginning warfarin therapy

Doctors prescribing blood thinners have had to go through a lengthy trial-and-error process to arrive at the optimal dose for their patients. But now the process can be faster and safer, thanks to research conducted at Washington University School of Medicine in St. Louis.

3 Sep 2007

Genetics determine optimal drug dose of warfarin

Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood , the journal of the American Society of Hematology.

22 Aug 2007

Genetic testing can be used to help personalize the therapeutic dosage of warfarin

Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Society of Hematology.

21 Aug 2007

FDA approves updated labeling for Warfarin (Coumadin)

The U.S. Food and Drug Administration has announced the approval of updated labeling for the widely used blood-thinning drug, Coumadin, to explain that people's genetic makeup may influence how they respond to the drug.

17 Aug 2007

Warfarin more effective than aspirin in prevention of stroke in people with atrial fibrillation

Warfarin is more effective than aspirin in prevention of stroke in people with a certain type of irregular heartbeat who are aged 75 or over, conclude authors of an Article published in this week's edition of The Lancet.

13 Aug 2007

Warfarin versus aspirin for stroke prevention

A study tracking nearly 1,000 over-75s at high risk of stroke has found that the anticoagulant drug warfarin cuts the risk by half in this older population without causing more side-effects than alternatives.

13 Aug 2007

Computers pass dosage test for thrombosis drugs

The largest ever study into the administration of blood thinning drugs like Warfarin has concluded that dosages calculated by computer are at least as safe and reliable as those provided by trained medical professionals.

From The University of Manchester 20 Jul 2007

Stroke in nonvascular atrial fibrillation

People with atrial fibrillation (AF) have irregular heart beats and have a tendency to form blood clots in the upper chambers (atria) of their hearts.

18 Jul 2007

Drug brand name can influence treatment decisions by patients

The brand name of a drug can strongly influence treatment decisions by patients, according to a randomized trial of decision aids by researchers from McMaster University.

22 May 2007

New treatments for brain hemorrhage

The first scientifically proven treatments for intracerebral hemorrhage, or "bleeding," strokes, are on the horizon, including a new drug that holds promise for slowing bleeding and limiting brain damage resulting from such a stroke, according to updated American Heart Association/American Stroke Association guidelines.

4 May 2007

FDA approves new indication for FRAGMIN for the extended treatment of symptomatic venous thromboembolism

The U.S. Food and Drug Administration (FDA) has approved a new indication for FRAGMIN (dalteparin sodium injection), for the extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence of VTE in patients with cancer.

4 May 2007

Cancer patients are at high risk for potential drug interactions

Potential drug interactions from prescribed medications are common among cancer patients and may cause unnecessary harm, according to a study in the April 18 Journal of the National Cancer Institute .

18 Apr 2007

Gleevec available to patients in post-surgical GIST study

Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

15 Apr 2007